Jul 30, 2024, 13:29
Denis Wirtz: MEK inhibitors have significant off-target toxicity and lack predictive biomarkers
Denis Wirtz, Vice Provost of Research at Johns Hopkins University, shared on X about recent paper by Paul M. Kuhn et al., titled “Local, Sustained, and Targeted Co-Delivery of MEK Inhibitor and Doxorubicin Inhibits Tumor Progression in E-Cadherin-Positive Breast Cancer” published on MDPI.
Authors: Paul M. Kuhn, Gabriella C. Russo, Ashleigh J. Crawford, Aditya Venkatraman, Nanlan Yang, Bartholomew A. Starich, Zachary Schneiderman, Pei-Hsun Wu, Thi Vo, Denis Wirtz and Efrosini Kokkoli
“MEK inhibitors have significant off-target toxicity and lack predictive biomarkers.
Here, we use a thermosensitive, biodegradable hydrogel with functionalized liposomes for sustained release of MEK inhibitors to E-cad-positive breast tumors.”
Source: Denis Wirtz/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12